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Abstract
Background: To evaluate optimal therapy and potential risk factors.
Methods: Data of DSRCT patients <40 years treated in prospective CWS trials 
1997‐2015 were analyzed.
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1 |  INTRODUCTION
Desmoplastic small round cell tumor (DSRCT) is a rare dis-
ease predominantly affecting adolescent and young adult 
males, which originates and spreads on peritoneal surfaces. 
Patients usually present with widespread intra‐abdomi-
nal metastatic tumors related to serosal surfaces similar to 
carcinomatosis.1 DSRCT consists of small round blue cell 
nests separated by desmoplastic stroma. It is characterized 
by the presence of t(11;22)(p13:q12) chromosomal translo-
cation which leads to the fusion of the Ewing sarcoma gene 
(EWSR1) to the Wilms’ tumor suppressor gene WT1.2 First 
described as a distinct entity in 1989 by Gerald and Rosai,3 
it remains poorly understood. Despite aggressive multimodal 
treatment, ~60%‐70% of patients succumb to disease within 
2‐3 years.4
2 |  PATIENTS AND METHODS
Eligible patients treated from 07/1997 to 06/2015 in the 
international European trials, CWS‐96,5 CWS‐2002P,6 
and CWS‐SoTiSaR conducted by the Cooperative 
Weichteilsarkomstudiengruppe CWS, had a confirmed 
diagnosis in central pathological review, aged <40 years, 
with no previous malignancy. All CWS trials were pro-
spective and approved by appropriate ethics committees. 
Written informed consent according to the declaration 
of Helsinki was obtained from patients or guardians/
parents. Data collection was performed as previously de-
scribed.6 Patients received multimodal treatment includ-
ing surgery, radiotherapy, and chemotherapy, according 
to the appropriate treatment protocols in use at the time 
of diagnosis.
Funding information
Supported by the German Childhood 
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Results: Median age of 60 patients was 14.5 years. Male:female ratio was 4:1. 
Tumors were abdominal/retroperitoneal in 56/60 (93%). 6/60 (10%) presented with a 
localized mass, 16/60 (27%) regionally disseminated nodes, and 38/60 (63%) with 
extraperitoneal metastases. At diagnosis, 23/60 (38%) patients had effusions, 4/60 
(7%) a thrombosis, and 37/54 (69%) elevated CRP. 40/60 (67%) patients underwent 
tumor resection, 21/60 (35%) macroscopically complete. 37/60 (62%) received chem-
otherapy according to CEVAIE (ifosfamide, vincristine, actinomycin D, carboplatin, 
epirubicin, etoposide), 15/60 (25%) VAIA (ifosfamide, vincristine, adriamycin, ac-
tinomycin D) and, 5/60 (8%) P6 (cyclophosphamide, doxorubicin, vincristine, ifosfa-
mide, etoposide). Nine received high‐dose chemotherapy, 6 received regional 
hyperthermia, and 20 received radiotherapy. Among 25 patients achieving complete 
remission, 18 (72%) received metronomic therapies. Three‐year event‐free (EFS) and 
overall survival (OS) were 11% (±8 confidence interval [CI] 95%) and 30% (±12 CI 
95%), respectively, for all patients and 26.7% (±18.0 CI 95%) and 56.9% (±20.4 CI 
95%) for 25 patients achieving remission. Extra‐abdominal site, localized disease, no 
effusion or ascites only, absence of thrombosis, normal CRP, complete tumor resec-
tion, and chemotherapy with VAIA correlated with EFS in univariate analysis. In 
multivariate analysis, significant factors were no thrombosis and chemotherapy with 
VAIA. In patients achieving complete remission, metronomic therapy with cyclo-
phosphamide/vinblastine correlated with prolonged time to relapse.
Conclusion: Pleural effusions, venous thrombosis, and CRP elevation were identi-
fied as potential risk factors. The VAIA scheme showed best outcome. Maintenance 
therapy should be investigated further.
K E Y W O R D S
C‐reactive protein, desmoplastic small round cell tumor, maintenance therapy, soft tissue sarcoma, 
Trousseau’s syndrome
   | 529SCHEER Et al.
2.1 | Staging and tumor distribution
Disease stage was classified according to IRS and TNM.7,8 
For purpose of this analysis, localized disease was defined 
as one single tumor mass; regionally disseminated disease 
as multiple lesions in one affected cavity, detected by radio-
logical assessment or inspection during surgical intervention. 
Extraperitoneal metastases were defined as lesions outside 
the affected cavity or in solid organs.
2.2 | Thrombosis
Venous thrombosis was diagnosed radiographically at diag-
nosis before implantation of a central venous line. No sys-
tematic screening for thromboses was performed.
2.3 | Pretreatment blood parameters
Coagulation parameters, blood counts, and C‐reactive pro-
tein values (CRP) were evaluated. D‐dimers were graded as 
normal (<500 µg/L), moderately increased (500‐2000 µg/L), 
and markedly increased (>2000 µg/L). Scoring for dissemi-
nated intravascular coagulation (DIC) was done according to 
the scoring system of the International Society on Thrombosis 
and Hemostasis (ISTH).9
The inflammatory scores neutrophil‐to‐lymphocyte ratio 
and platelet‐to‐lymphocyte ratio were calculated by divid-
ing the absolute neutrophil or platelet count, respectively, by 
the absolute lymphocyte count. The median was chosen as 
threshold. CRP was considered elevated when >5 mg/L.
2.4 | First‐line chemotherapy
The induction therapy used was trial‐dependent (Table S1). 
Early diagnosed patients had received the P6‐scheme ac-
cording to Kushner.10 Regional hyperthermia in combination 
with platinum‐based chemotherapy11 and high‐dose chemo-
therapy with autologous stem cell rescue were administered 
on an individual basis.
Hyperthermic intraperitoneal chemotherapy (HIPEC) 
procedures with cisplatin and doxorubicin in combination 
with tumor resections were performed, a decision made by 
the treating oncologist.
2.5 | Maintenance chemotherapy
Remission was defined as no macroscopic residuals at ther-
apy end (achieved with surgery and/or chemotherapy and/or 
radiotherapy). Maintenance chemotherapy with oral trofos-
famide, idarubicin, etoposide (O‐TIE),12 or with cyclophos-
phamide per os, vinblastine intravenously (Cyc/Vbl)6,13,14 
was administered (Table S1) trial‐dependent or individually. 
Some patients received individual therapy with irinotecan/
temozolomide or irinotecan/trabectidin. In addition to sur-
vival from diagnosis, time to relapse was calculated from end 
of intensive chemotherapy to eliminate the influence of dif-
ferent lengths of intensive therapies.
2.6 | Response evaluation
Response was assessed after three chemotherapy courses. 
For purpose of this analysis, response assessment was based 
on the CWS evaluation criteria for primary tumors15,16: par-
tial response ≥2/3 volume reduction, minor response ≥1/3 
but <2/3 reduction, objective response <1/3 reduction, stable 
disease status idem, progression (≥1/10 volume increase).
In regionally disseminated nodular disease with variable 
response, the lesion showing the least volume reduction was 
evaluated.
2.7 | Local treatment
CWS protocols recommended local treatment of DSRCT 
analogous to non‐rhabdomyosarcoma (NRSTS). Overall 
treatment strategies did not change substantially over the 
years. The mainstay of treatment for NRSTS was primary 
surgery with preferably complete or wide‐ranging resection 
after biopsy. In metastatic disease, primary excision or biopsy 
of the primary tumor and/or metastases was performed and 
systemic therapy was administered to reduce tumor volume 
and improve respectability. This was followed by secondary 
surgery if feasible. Best surgery was defined as the best sur-
gical result obtained at the end of treatment irrespective of 
procedure numbers. The surgical result was categorized as 
biopsy only, presence of macroscopic [R2], or microscopic 
[R1] residual tumor or as resection with free margins [R0].
Radiotherapy was to be administered with a total dose 
of 32‐54.4 Gy (dose reduced hyperfractionated/acceler-
ated radiotherapy) depending on primary resection status. 
Postoperative radiotherapy of the primary tumor (and me-
tastases) was recommended. External beam irradiation with 
44.8 Gy was recommended if a microscopically complete 
resection (R0) was not performed. In CWS‐2002P, the rec-
ommendation was extended to include patients in whom an 
R0‐resection had been performed if tumor size was >5 cm or 
age >10 years. In SoTiSaR, radiotherapy with 50.4 Gy (con-
ventional fractionated irradiation) was added as an alterna-
tive. However, individual physician decisions did not always 
follow these recommendations.
2.8 | Statistical methods
Statistics were calculated using SPSS® 24 (Armonk, New 
York, NY, USA). Comparison of distribution was performed 
with the chi‐square test. Event‐free survival [EFS] and over-
all survival [OS] were calculated using the Kaplan‐Meier 
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estimator.17 For OS, time from diagnosis to death or last 
follow‐up was calculated, for EFS time from diagnosis to 
relapse/progression, death, or last follow‐up. Confidence in-
tervals [CI] for the Kaplan‐Meier estimator were computed 
using Greenwoods Formula18 and stated at 95%‐level. For 
comparison of EFS and OS levels, the log‐rank test was 
used.
Multivariate analysis was conducted using Cox's pro-
portional hazards regression method to establish indepen-
dent prognostic significance. A stepwise variable selection 
procedure (combination of forward and backward selection 
techniques) was applied to covariates with P‐value of at least 
0.1 in EFS at univariate analysis. Hazard ratios (HRs) with 
95% confidence intervals, calculated according to the Wald 
method, are reported for significant variables. Statistics were 
calculated using IBM SPSS® 24 for all other analyses.
3 |  RESULTS
3.1 | Patient and tumor characteristics
Sixty patients registered from Germany (n = 51), Poland 
(n = 4), Sweden (n = 2), Austria (n = 2), and Switzerland 
(n = 1) were eligible. Median age at diagnosis was 14.5 years 
(6.0‐38.0). Male:female ratio was 4:1 (Table 1). 56/60 pa-
tients (93%) had tumors in the abdominal cavity (abdominal 
and/or retroperitoneal). Four patients had extra‐abdominal 
tumors, which included four thoracic, one paratesticular, and 
one parotid gland (all EWSR1‐WT1‐positive). 40/60 (67%) 
tumors were larger than 10 cm.
Six patients had a localized tumor (all EWSR1‐WT1‐pos-
itive, 3 extra‐abdominal, 3 abdominal). An additional patient 
with a single primary in the abdomen also had extraperito-
neal metastases (liver, lung, mediastinal lymph nodes).
The tumor was regionally disseminated in 53/60 patients 
(88%). Thirty‐seven of these 53 (70%) had extraperitoneal 
metastases (Table S2).
23/60 patients (38%) had effusions, 14 ascites, six ascites 
in combination with pleural effusions, and three presented 
with pleural effusion only. Malignant cells were evident in 
11/18 examined effusions.
Four patients presented with thrombosis before implanta-
tion of a central catheter. Two had a thrombosis in the vena 
cava, one in the iliac with extension into femoral and popli-
teal veins while the other had a brachiocephalic and jugular 
thrombosis.
In 56/60 patients, pretreatment laboratory parameters 
were available, which included coagulation results in 50 
(83%). In 15 (25%), which included only two of the patients 
with thrombosis, D‐dimers were determined. D‐dimers were 
normal (n = 2), moderately increased (n = 6), and mark-
edly increased (n = 7); the latter included two patients with 
thrombosis. Scoring for DIC according to the ISTH9 was 
possible in 12 (20%) patients. All patients scored below 5, 
defined as nonovert DIC (n = 2 score 0; n = 4 score 2; n = 6 
score 3).
Leukocytes ranged from 4.07 to 24.00/nL (median 8.1/
nL) in 55/56 patients. Median neutrophil‐to‐lymphocyte and 
platelet‐to‐lymphocyte ratios were 3.09 (0.56‐9.20) and 170 
(50.15‐483.67) in 50 and 54 patients, respectively, with avail-
able data, and 2.96 (1.14‐9.20) and 165 (61.63‐435.16) in 23 
and 25 patients achieving remission. Platelets ranged from 
189 to 566/nL in 56/56 patients. 16/56 (27%) had thrombo-
cytes >350/nL. CRP values were available for 54/56 (90%) 
and were elevated in 37/54 (69%).19
3.2 | Treatment
37/60 (62%) patients received chemotherapy according to the 
CEVAIE regimen12 (ifosfamide, vincristine, actinomycin D, 
carboplatin, epirubicin, etoposide), 15/60 (25%) according to 
VAIA6 (ifosfamide, vincristine, adriamycin, actinomycin D) 
and 5/60 (8%) with P6‐regimen10 (cyclophosphamide, doxo-
rubicin, vincristine, ifosfamide, etoposide).
Two patients received alternative therapy (NB95 and 
Hyper‐PEI, respectively). A single patient did not receive 
chemotherapy due to severe mental retardation.
Response to chemotherapy ranged from partial response to 
progression (Table 2). In six patients with regionally dissem-
inated disease, a mixed response with reduction of some and 
stable or increased volume in other lesions was documented.
Nine patients received high‐dose chemotherapy with 
autologous stem cell transplantation, and six other patients 
were treated with regional hyperthermia in combination 
with platinum‐based chemotherapy11 in addition to standard 
chemotherapy.
21/60 (35%) patients underwent complete resection of pri-
mary tumor manifestations (R0 n = 5, R1 n = 16). Two pa-
tients with R1 resection suffered disease progression shortly 
after resection and therefore were not considered as having 
achieved remission. Five patients were treated with HIPEC, 
three following R1‐ and two after R2‐resection.
3.3 | Outcome
Overall, 51/60 patients died, 49 of disease and two of 
therapy‐related causes (organ failure after chemotherapy, 
postoperative complications with peritonitis after anus 
praeter relocation). With a median follow‐up of 3.2 years 
(1.2‐10.6), 9/60 patients were alive, six in 1st, one in 
2nd remission, one lost to follow‐up without ever having 
achieved remission, and one in first relapse with active dis-
ease (Table S4).
Based upon follow‐up data as of March 2017, 3‐year EFS 
and 3‐year OS were 11% (±8 CI 95%) and 30% (±12 CI 95%; 
Figure 1).
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F I G U R E  1  Event-free and overall survival probability of 60 DSRCT patients. Event-free survival probability according to the tumor 
distribution, the existence of effusions, thrombosis, elevated pretreatment CRP-value, and the conducted first-line chemotherapeutic regimens and 
best surgical result at any time in first-line therapy
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25/60 patients (42%) achieved a complete remission at all 
disease sites, 6/25 (10%) remained in continuous remission 
and 19/25 (32%) remained in relapsed (Figure 2). For those 
25 patients achieving remission, 3‐year EFS and 3‐year OS 
were 26.7% (±18.0 CI 95%) and 56.9% (±20.4 CI 95%), 
respectively.
35/60 patients (58%) did not achieve remission and died in 
a median of 1.5 years.
Among the four patients initially presenting with throm-
bosis, two showed progression while still on chemotherapy, 
while the remaining suffered early recurrences. None sur-
vived longer than 1.5 years.
3.4 | Outcome according to surgery
In all those 19 patients who only underwent biopsy as best 
surgical procedure, an event (disease progression or re-
lapse) was documented in a median of 0.7 years (range 
0.2‐3.3). Median overall survival was 1.6 years (0.6‐5.3). 
None survived. In those other 19 patients with R2‐resec-
tion as best surgical result at any time, all had an event in 
a median of 1.0 years (0.2‐5.2). Median overall survival 
was 1.7 years (0.3‐6.4). Two were alive at the cutoff date, 
thereof one lost in progression and the other in first re-
lapse with active disease. Of those 16 patients with R1 re-
section, 13 had an event in a median of 1.2 years (0.1‐2.4). 
Median overall survival was 2.6 years (1.1‐6.8). Four pa-
tients were in first remission at the cutoff date with a fol-
low‐up of 5.5, 3.2, 2.5, and 2.5 years, respectively. Five 
were alive. Of those five patients with R0‐resection, 3 had 
an event in a median of 0.6 years (0.3‐3.0). Median over-
all survival was 4.2 years (1.0‐10.6). Two were alive at 
the cutoff date with a follow‐up of 10.6 and 6.1 years, 
respectively.
3.5 | Outcome according to chemotherapy
The five patients treated according to the P6‐regimen 
had a median EFS of 12.9 months (7.6‐16.5), 15 treated 
with VAIA 29.4 months (1‐127.7), and 37 who received 
CEVAIE 12.0 months (22.1‐306.7). The remaining patient 
survived 9 months with palliative care. The VAIA scheme 
correlated with increased chance of R0 or R0/R1 resection 
(Table S3).
F I G U R E  2  Flow diagram of evaluated patients
DSRCT in database 
<40 y 1997 - 2015 
n = 62
Eligible for analysis
n = 60 (100%)
Diagnosis not confirmed at 2. retrospective 
pathological reference review 
n = 2
Complete remission
n = 25 (42%)
Complete remission not achieved
n = 35 (58%)
Continuous remission
n =  6 (10%)
Median survival 1.5 y (0.3 – 4.9)
Current status:
Dead of tumor n = 33
Deadof therapy n = 1
Lost in progression n = 1
Relapse
n = 19 (32%)
Median follow-up 4.4 y (2.5 –10.6)
Current status:
Alive: 6
Median time to relapse 1.7 y (0.3 – 5.2)
Second remission achieved n = 4
Third remission achieved n = 1
Median survival from point of relapse 
1.2 y (0.2 – 5.7)
Currentstatus: 
Alive in 2. remission n = 1
Alive with active disease n = 1
Deadof postoperative complications after anus praeter-
Relocation in 2. remission n = 1 
Dead of tumor n = 16
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Potential correlations between maintenance therapy 
and outcome were analyzed in the subgroup of 25 pa-
tients achieving remission (Table 2, Figure 3). In six pa-
tients without maintenance therapy, the median time to 
relapse calculated from the end of intensive chemother-
apy was 8.0 months (3.4‐20.2), in 11 patients with O‐
TIE 17.2 months (5.2‐31.8), in five patients with Cyc/
Vbl 56.5 months (7.8‐122.0), and in three patients with 
irinotecan‐containing metronomic therapy 17.4 months 
(11.3‐35.6).
3.6 | Pattern of relapse
Among those 19 patients with relapse, five suffered recur-
rence with merely intraperitoneal lesions. Nine other pa-
tients suffered metastatic recurrence with extraperitoneal 
lesions at different sites (n = 1 lung and bone lesions, n = 1 
lymph node supraclavicular, n = 1 bone lesions, n = 1 me-
diastinal mass and lung lesions, n = 1 lung and liver lesions, 
n = 1 lung lesions, n = 1 one spleen lesion, n = 1 liver and 
brain lesions, and n = 1 pleural sarcomatosis). Five patients 
suffered relapse with combined intra‐ and extraperitoneal 
lesions. Extraperitoneal lesions were documented at liver 
and skin (n = 1), paratracheal and bone (n = 1), thoracal 
and lung (n = 1), thoracic lesions subpleural (n = 1), the 
site of the affected distant lymph nodes was not documented 
(n = 1).
3.7 | Uni‐ and multivariate analyses
In univariate analysis, extra‐abdominal site, localized dis-
ease, no effusion or ascites only, absence of thrombosis, and 
normal CRP were associated with a significantly increased 
EFS (Table 1). Univariate analysis of metastatic sites did not 
show any differences in EFS whereas the existence of liver 
metastases correlated with reduced OS (Table S2).
Among first‐line treatment, chemotherapy with VAIA and 
complete resection of all primary tumor lesions at any time 
correlated with prolonged EFS (Table 2).
The distribution of prognostic factors among the chemo-
therapeutic regimens is shown in Table S3.
A multivariate analysis was conducted to establish in-
dependent prognostic significance of the evaluated factors 
(Table 3). Absence of thrombosis and chemotherapy accord-
ing to the VAIA regimen remained significant.
4 |  DISCUSSION
This study of 60 DSRCT patients confirms the poor progno-
sis. A small subgroup with reasonable outlook for long‐term, 
disease‐free survival could be identified, three individuals 
with localized and extra‐abdominal disease, without pleural 
effusions, or thrombosis and normal CRP who were subse-
quently treated by complete tumor resection in conjunction 
F I G U R E  3  The effect of additional maintenance therapy after the end of intensive chemotherapy evaluated in 25 patients who achieved a first 
complete remission
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with VAIA chemotherapy. All three patients were disease‐
free at last follow‐up (6.1, 5.5, 2.5 years).
An inherent weakness of this study is the small number 
of patients due to the fact that DSRCT has only been re-
cently described and is a very rare tumor. Nevertheless, to 
the best of our knowledge, it is the largest series of DSRCT 
patients enrolled in prospective trials to date. However, our 
analysis is retrospective and the base‐line blood parameters 
are nonspecific. Further evaluation should be prospective and 
standardized.
Characteristics were similar to previous reports.20,21 
Patients were principally adolescent, male and had large and 
widespread abdominal and/or retroperitoneal tumors. The 
majority had extraperitoneal metastases. No typical meta-
static pattern was identifiable. No specific risk for disease 
progression or relapse of any specific metastatic site could 
be revealed. Nevertheless, though the existence of liver me-
tastases did not correlate with reduced EFS in our series, it 
correlated with a reduced overall survival probability. Liver 
metastases have been observed as a potential prognostic 
factor before.22,23 No specific pattern of disease recurrence 
could be determined; therefore, we were not able to identify 
specific treatment weaknesses.
In contrast to the literature, existence of extraperitoneal 
metastases did not correlate with survival.1,24,25 This sup-
posed difference might have been caused by the fact that oth-
ers had not differentiated between localized and regionally 
disseminated disease. However, others had estimated tumor 
burden based on peritoneal cancer index but survival did not 
differ.24,25
In contrast to all other solid tumors, size and evidence of 
distant metastases did not correlate with survival. One cause 
might be the unique nature of dissemination. It seems that 
from the point, the cells lose the ability to organize within 
a single node and start disseminating into multiple nodules, 
survival decreases significantly. It remains to be elucidated 
Variables EFS hazard ratio
Confidence 
interval (95%) P‐value
Site of primary tumor
Abdominal 1
Extra‐abdominal 1.958 0.12‐32.13 0.638
Tumor distribution
Localized 1
Regionally disseminated 7.837 0.59‐104.90 0.120
Extraperit. Metastases 5.582 0.49‐63.21 0.165
Effusions
No effusion 1
Ascites 1.044 0.44‐2.50 0.923
Pleural effusion 0.684 0.17‐2.80 0.597
Ascites + pleural effusion 2.165 0.35‐13.57 0.410
Venous thrombosis
No 1
Yes 10.96 2.77‐43.31 0.001
Elevation of CRP
No 1
Yes 1.231 0.50‐3.00 0.648
Chemotherapy
VAIA 1
CEVAIE 3.17 1.13‐8.90 0.029
P6 2.58 0.47‐14.26 0.277
Best surgery at any time
R0 1
R1 0.75 0.13‐4.19 0.741
R2 1.22 0.24‐6.15 0.807
Biopsy 0.88 0.15‐5.09 0.890
Bold values indicate statistical significance
T A B L E  3  Multivariate analysis of 
factors predicting increased risk of 
progression or relapse
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whether this is due to the fact that local therapy is restricted 
or whether regionally disseminated disease indicates consid-
erably more aggressive biology.
Though the presence of effusions has been described in 
DSRCT,26 prognostic impact is unclear. In our series, pleural 
effusions correlated with inferior survival.
Four patients aged 8, 10, 11, and 17 years presented with 
venous thrombosis—detected coincidentally in the initial 
staging investigations. The association between thrombosis 
and cancer is well known as the Trousseau's syndrome.27 
Occurrence varies by age and cancer type.28-32 Pathogenesis is 
multifactorial.33 A positive association can be observed with 
1‐year mortality of the cancer type as a measure of biological 
aggressiveness and associated thrombogenic potential.29,34 In 
our series, coagulation activation with thrombus formation 
seems to indicate more aggressive disease. Unfortunately, de-
tailed analysis of the coagulation cascade was not possible. In 
only 15/60 (25%) patients, the necessary coagulation values 
including D‐dimers were determined. Elevation was evident 
in 13 (86%). It is debatable, whether D‐dimers alone or the 
ISTH scoring system is sufficient to capture or even quantify 
the pivotal phenomenon.35,36
One contributing factor to coagulation activation is in-
flammation, which plays an important role in tumorigenesis.37 
Inflammatory scores are predictive in numerous cancers.19,38 
In our series, merely CRP correlated with survival. As there 
are no acknowledged standard values for the applied ratios,39 
the median was chosen.40 However, the predictive signifi-
cance of CRP suggests need to determine clinical utility. It 
seems worth mentioning that among those 17 patients with 
normal CRP, five had localized, four regionally distributed, 
and eight widespread disease with extraperitoneal metastases.
Of interest are the underlying mechanisms. Malignancy 
is characterized by destructive tumor cell invasion of vas-
cularized organ tissue and formation of leaky new vessels, 
so‐called tumor angiogenesis. The procoagulant phenotype 
is likely to have profound effect on the hemostatic system 
as result of plasma leakage into the interstitial space, se-
cretion of inflammatory cytokines, and direct invasion of 
tumor cells into blood or lymphatic vessels.27 Coagulation 
activation, inflammation, and tumor biology form a trian-
gular network with reciprocal interactions.33,41 The elu-
cidation of these mechanisms might help to understand 
DSRCT biology.
The most effective chemotherapeutic regime still is debated. 
Most combinations are based on alkylating agents, similar to 
those in other small round cell tumors or Ewing sarcomas, 
which also carry EWSR1 fusions.25,42 Farhat reported five 
patients with disease stabilization lasting 4‐9 months using a 
regimen consisting of cisplatin, etoposide, cyclophosphamide, 
and an anthracycline.43 Kushner reported 12 patients with me-
dian survival of 19 months with the P6‐protocol.10 Bertuzzi 
reported median survival of 14 months in 17 patients treated in 
two prospective studies with induction chemotherapy of ifos-
famide, epirubicin, and vincristine.44,45 Wong reported median 
time to progression of 14.6 months in 13 patients treated ac-
cording to the VIDE‐regimen (vincristine, ifosfamide, doxoru-
bicin, etoposide).20 Another report states survival of 1.7 years 
in a single case with VIDE.46 The use of other agents has been 
reported, including irinotecan, temozolomide, and vinorel-
bine, but none of them showed superiority.47,48 Evidence is 
emerging on trabectedin.49-53 Activity was reported for pazo-
panib54,55 and eribulin.56 A recent report gave negative results 
for imatinib.57 Limited activity of the antiangiogenics suni-
tinib, sorafenib, and bevacizumab is reported.58-60
In our series chemotherapy according to the VAIA 
scheme correlated with longer EFS than did the other in-
vestigated regimes. The median EFS of 15 patients treated 
with VAIA was 29.4 months. To the best of our knowledge, 
this is the first assessment of the VAIA scheme in DSRCT. 
Though the distribution of prognostic factors differed 
among the three analyzed chemotherapeutic regimens, the 
independent effect of the VAIA scheme was proven in the 
Cox regression analysis.
However, the fact that response to chemotherapy did not 
correlate with outcome is striking. 2/6 (33%) survivors had 
progressive disease. They were then treated with aggressive 
surgery.
6/60 (10%) patients showed mixed response of different 
tumor nodes suggesting heterogenous biology, which should 
be considered when adopting targeted therapeutic approaches.
In accordance with the recent literature, high‐dose che-
motherapy did not correlate with survival.61 The value of hy-
perthermia remains to be specified. However, in our series, 
patients did not benefit.
While there is considerable investment in the develop-
ment of innovative therapies, metronomic approaches have 
been underinvestigated. In our series, metronomic therapy 
with cyclophosphamide/vinblastine correlated with pro-
longed time to relapse.
The crucial and decisive role of surgery can be con-
firmed.42,62 In our series, no patient who did not have a 
R0 resection or R1 resection survived long‐term or was 
disease‐free at the cutoff date. More precisely, of those 38 
patients with only biopsy or R2‐resection, only two were 
alive at the cutoff date, thereof one lost in progression and 
the other in first relapse with active disease. However, the 
feasibility of surgery due to extensively disseminated dis-
ease remains a problem. Interestingly, in the subgroup of 
25 patients achieving remission, extent of surgery was not 
predictive of outcome. Two patients who only underwent 
biopsy achieved remission with chemotherapy alone, one 
with simultaneous irradiation. Unfortunately, the addi-
tional value of HIPEC1,24,63,64 cannot be further elucidated 
as only 5 patients with different resection results received 
HIPEC.
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Although the CWS trials included radiotherapy rec-
ommendations, most patients were irradiated following an 
individual concept due to extensive disease. Radiotherapy 
mainly consisted of focused irradiation to particular tumor 
sites or nonresectable nodes. Whole‐abdominal irradiation 
was performed in two patients. Thus, a reliable conclusion 
with regard to the specific effect of radiotherapy in DSRCT 
remains difficult. In our series, irradiation did not correlate 
with survival. Other authors suggested that a multimodal 
concept combining chemotherapy, surgery, and irradiation 
enables prolonges survival.25,63,65 In the future, the appli-
cation and evaluation of standardized radiotherapeutic con-
cepts and/or techniques are necessary to specify its potential 
benefit.22,23
Nevertheless, in our series no specific pattern of disease 
recurrence was evident, so we were not able to identify spe-
cific treatment weaknesses.
In summary, the VAIA scheme could be specified as best 
chemotherapy in a multivariable model. The effect of main-
tenance therapy warrants further investigation. Pleural effu-
sions, venous thrombosis, and CRP elevation were identified 
as novel potential risk factors for adverse outcomes. The 
elucidation of the underlying coagulation and inflammatory 
mechanisms may lead to a better understanding of disease 
biology, especially when investigating the observed coagula-
tory and inflammatory phenomena in conjunction with ge-
netic analysis.
ACKNOWLEDGMENT
We are indebted to the personnel of all participating insti-
tutions and thank all patients, parents, and guardians for 
their willingness to participate in the CWS trials. We thank 
Iris Veit‐Friedrich, Simone Feuchtgruber, and Agniezska 
Bakowska CDM for their excellent data management and 
Mary Morgan for review of the manuscript.
CONFLICT OF INTEREST
None of the authors declared a conflict of interest related to 
the submitted material.
ORCID
Monika Scheer  https://orcid.org/0000-0002-0665-6268 
Monika Sparber‐Sauer  https://orcid.
org/0000-0001-9551-2399 
REFERENCES
 1. Hayes‐Jordan A, Green HL, Lin H, et al. Complete cytoreduction 
and HIPEC improves survival in desmoplastic small round cell 
tumor. Ann Surg Oncol. 2014;21(1):220‐224.
 2. Ladanyi M, Gerald W. Fusion of the EWS and WT1 genes 
in the desmoplastic small round cell tumor. Cancer Res. 
1994;54(11):2837‐2840.
 3. Gerald WL, Rosai J. Case 2. Desmoplastic small cell tumor with 
divergent differentiation. Pediatr Pathol. 1989;9(2):177‐183.
 4. Stiles ZE, Dickson PV, Glazer ES, et al. Desmoplastic small round 
cell tumor: a nationwide study of a rare sarcoma. J Surg Oncol. 
2018;117(8):1759‐1767.
 5. Modritz D, Ladenstein R, Potschger U, et al. Treatment for soft tis-
sue sarcoma in childhood and adolescence. Austrian results within 
the CWS 96 study. Wien Klin Wochenschr. 2005;117(5‐6):196‐209.
 6. Koscielniak E, Kosztyla D, Dantonello T, et al. Report of the 
CWS‐2002‐P study: treatment results for soft tissue sarcomas (STS) in 
childhood and adolescence. Pediatr. Blood Cancer. 2013;60(S3):32.
 7. Harmer M, Denoix P, Hamperl H. The TNM‐system. Aktuelle 
Probl Chir. 1970;14:25‐36.
 8. Scheer M, Dantonello T, Brossart P, et al. Importance of whole‐
body imaging with complete coverage of hands and feet in alveolar 
rhabdomyosarcoma staging. Pediatr Radiol. 2018;48:648‐657.
 9. Taylor FB Jr, Toh CH, Hoots WK, et al. Towards definition, clinical 
and laboratory criteria, and a scoring system for disseminated in-
travascular coagulation. Thromb Haemost. 2001;86(5):1327‐1330.
 10. Kushner BH, LaQuaglia MP, Wollner N, et al. Desmoplastic small 
round‐cell tumor: prolonged progression‐free survival with aggres-
sive multimodality therapy. J Clin Oncol. 1996;14(5):1526‐1531.
 11. Wessalowski R, Schneider DT, Mils O, et al. Regional deep hy-
perthermia for salvage treatment of children and adolescents with 
refractory or recurrent non‐testicular malignant germ‐cell tumours: 
an open‐label, non‐randomised, single‐institution, phase 2 study. 
Lancet Oncol. 2013;14(9):843‐852.
 12. Klingebiel T, Boos J, Beske F, et al. Treatment of children with 
metastatic soft tissue sarcoma with oral maintenance compared to 
high dose chemotherapy: report of the HD CWS‐96 trial. Pediatr 
Blood Cancer. 2008;50(4):739‐745.
 13. Scheer M, Dantonello T, Hallmen E, et al. Primary metastatic 
synovial sarcoma: experience of the CWS Study Group. Pediatr 
Blood Cancer. 2016;63(7):1198‐1206.
 14. Scheer M, Dantonello T, Hallmen E, et al. Synovial sarcoma recur-
rence in children and young adults. Ann Surg Oncol. 2016;23(Suppl 
5):618‐626.
 15. Koscielniak E, Jurgens H, Winkler K, et al. Treatment of soft tissue sar-
coma in childhood and adolescence. A report of the German Cooperative 
Soft Tissue Sarcoma Study. Cancer. 1992;70(10):2557‐2567.
 16. Dantonello TM, Stark M, Timmermann B, et al. Tumour volume 
reduction after neoadjuvant chemotherapy impacts outcome in 
localised embryonal rhabdomyosarcoma. Pediatr Blood Cancer. 
2015;62(1):16‐23.
 17. Kaplan EL, Meyer P. Non‐parametric estimation from incomplete 
observations. J Am Stat Assoc. 1958;53:457‐481.
 18. Greenwood M. Reports on public health and medical subjects. 
The errors of sampling of the survivorship tables. London: HM 
Stationery Office; 1926.
 19. Dolan RD, Lim J, McSorley ST, et al. The role of the systemic 
inflammatory response in predicting outcomes in patients with 
operable cancer: Systematic review and meta‐analysis. Sci Rep. 
2017;7(1):16717.
 20. Wong HH, Hatcher HM, Benson C, et al. Desmoplastic small 
round cell tumour: characteristics and prognostic factors of 41 pa-
tients and review of the literature. Clin Sarcoma Res. 2013;3(1):14.
   | 541SCHEER Et al.
 21. Lettieri CK, Garcia‐Filion P, Hingorani P. Incidence and outcomes 
of desmoplastic small round cell tumor: results from the surveil-
lance, epidemiology, and end results database. J Cancer Epidemiol. 
2014;2014:680126.
 22. Osborne EM, Briere TM, Hayes‐Jordan A, et al. Survival and tox-
icity following sequential multimodality treatment including whole 
abdominopelvic radiotherapy for patients with desmoplastic small 
round cell tumor. Radiother Oncol. 2016;119(1):40‐44.
 23. Desai NB, Stein NF, LaQuaglia MP, et al. Reduced toxicity with 
intensity modulated radiation therapy (IMRT) for desmoplastic 
small round cell tumor (DSRCT): an update on the whole abdom-
inopelvic radiation therapy (WAP‐RT) experience. Int J Radiat 
Oncol Biol Phys. 2013;85(1):e67‐72.
 24. Hayes‐Jordan A, Green H, Lin H, et al. Cytoreductive surgery and 
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for children, 
adolescents, and young adults: the first 50 cases. Ann Surg Oncol. 
2015;22(5):1726‐1732.
 25. Honore C, Amroun K, Vilcot L, et al. Abdominal desmoplastic 
small round cell tumor: multimodal treatment combining chemo-
therapy, surgery, and radiotherapy is the best option. Ann Surg 
Oncol. 2015;22(4):1073‐1079.
 26. Hayes‐Jordan A, LaQuaglia MP, Modak S. Management of 
desmoplastic small round cell tumor. Semin Pediatr Surg. 
2016;25(5):299‐304.
 27. Varki A. Trousseau's syndrome: multiple definitions and multiple 
mechanisms. Blood. 2007;110(6):1723‐1729.
 28. Walker AJ, Card TR, West J, et al. Incidence of venous throm-
boembolism in patients with cancer ‐ a cohort study using linked 
United Kingdom databases. Eur J Cancer. 2013;49(6):1404‐1413.
 29. Timp JF, Braekkan SK, Versteeg HH, et al. Epidemiology of cancer‐
associated venous thrombosis. Blood. 2013;122(10):1712‐1723.
 30. Athale U, Siciliano S, Thabane L, et al. Epidemiology and clinical 
risk factors predisposing to thromboembolism in children with can-
cer. Pediatr Blood Cancer. 2008;51(6):792‐797.
 31. Athale U, Cox S, Siciliano S, et al. Thromboembolism in children 
with sarcoma. Pediatr Blood Cancer. 2007;49(2):171‐176.
 32. Paz‐Priel I, Long L, Helman LJ, et al. Thromboembolic events in 
children and young adults with pediatric sarcoma. J Clin Oncol. 
2007;25(12):1519‐1524.
 33. Dicke C, Langer F. Pathophysiology of Trousseau's syndrome. 
Hamostaseologie. 2015;35(1):52‐59.
 34. Ahlbrecht J, Dickmann B, Ay C, et al. Tumor grade is associated 
with venous thromboembolism in patients with cancer: results 
from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 
2012;30(31):3870‐3875.
 35. Asakura H, Takahashi H, Uchiyama T, et al. Proposal for new di-
agnostic criteria for DIC from the Japanese Society on Thrombosis 
and Hemostasis. Thromb J. 2016;14:42.
 36. Soundar EP, Jariwala P, Nguyen TC, et al. Evaluation of the 
International Society on Thrombosis and Haemostasis and institu-
tional diagnostic criteria of disseminated intravascular coagulation 
in pediatric patients. Am J Clin Pathol. 2013;139(6):812‐816.
 37. Diakos CI, Charles KA, McMillan DC, et al. Cancer‐related 
inflammation and treatment effectiveness. Lancet Oncol. 
2014;15(11):e493‐503.
 38. Nayak A, McDowell DT, Kellie SJ, et al. Elevated preoperative 
neutrophil‐lymphocyte ratio is predictive of a poorer progno-
sis for pediatric patients with solid tumors. Ann Surg Oncol. 
2017;24(11):3456‐3462.
 39. Forget P, Khalifa C, Defour JP, et al. What is the normal 
value of the neutrophil‐to‐lymphocyte ratio? BMC Res Notes. 
2017;10(1):12.
 40. Dolan RD, McSorley ST, Horgan PG, et al. The role of the sys-
temic inflammatory response in predicting outcomes in patients 
with advanced inoperable cancer: systematic review and meta‐
analysis. Crit Rev Oncol Hematol. 2017;116:134‐146.
 41. Langer F, Bokemeyer C. Crosstalk between cancer and hae-
mostasis. Implications for cancer biology and cancer‐associ-
ated thrombosis with focus on tissue factor. Hamostaseologie. 
2012;32(2):95‐104.
 42. Lal DR, Su WT, Wolden SL, et al. Results of multimodal treat-
ment for desmoplastic small round cell tumors. J Pediatr Surg. 
2005;40(1):251‐255.
 43. Farhat F, Culine S, Lhomme C, et al. Desmoplastic small round cell 
tumors: results of a four‐drug chemotherapy regimen in five adult 
patients. Cancer. 1996;77(7):1363‐1366.
 44. Bertuzzi A, Castagna L, Nozza A, et al. High‐dose chemother-
apy in poor‐prognosis adult small round‐cell tumors: clinical 
and molecular results from a prospective study. J Clin Oncol. 
2002;20(8):2181‐2188.
 45. Bertuzzi A, Castagna L, Quagliuolo V, et al. Prospective study 
of high‐dose chemotherapy and autologous peripheral stem cell 
transplantation in adult patients with advanced desmoplastic small 
round‐cell tumour. Br J Cancer. 2003;89(7):1159‐1161.
 46. Frank JA, Ranft A, Paulussen M, et al. Results for patients with 
sarcoma not otherwise specified and other diagnoses than Ewing 
sarcoma treated according to the Euro‐EWING 99 trial. Pediatr 
Blood Cancer. 2017;64(10):e26524.
 47. Rosoff PM, Bayliff S. Successful clinical response to irinote-
can in desmoplastic round blue cell tumor. Med Pediatr Oncol. 
1999;33(5):500‐503.
 48. Ferrari A, Grosso F, Stacchiotti S, et al. Response to vinorelbine 
and low‐dose cyclophosphamide chemotherapy in two patients 
with desmoplastic small round cell tumor. Pediatr Blood Cancer. 
2007;49(6):864‐866.
 49. Chuk MK, Aikin A, Whitcomb T, et al. A phase I trial and 
pharmacokinetic study of a 24‐hour infusion of trabecte-
din (Yondelis(R), ET‐743) in children and adolescents with 
relapsed or refractory solid tumors. Pediatr Blood Cancer. 
2012;59(5):865‐869.
 50. Lopez‐Gonzalez A, Cantos B, Tejerina E, et al. Activity of tra-
bectidin in desmoplastic small round cell tumor. Med Oncol. 
2011;28(Suppl 1):S644‐646.
 51. Brunetti AE, Delcuratolo S, Lorusso V, et al. Third‐line trabectedin 
for a metastatic desmoplastic small round cell tumour treated with 
multimodal therapy. Anticancer Res. 2014;34(7):3683‐3688.
 52. Frezza AM, Whelan JS, Dileo P. Trabectedin for desmoplas-
tic small round cell tumours: a possible treatment option? Clin 
Sarcoma Res. 2014;4:3.
 53. Verret B, Honore C, Dumont S, et al. Trabectedin in advanced des-
moplastic round cell tumors: a retrospective single‐center series. 
Anticancer Drugs. 2017;28(1):116‐119.
 54. Ikeue T, Ohi I, Noguchi S, et al. Desmoplastic small round cell 
tumor of the pleura successfully treated with a lower dose of pazo-
panib. Intern Med. 2016;55(17):2463‐2467.
 55. Menegaz BA, Cuglievan B, Benson J, et al. Clinical activity of pa-
zopanib in patients with advanced desmoplastic small round cell 
tumor. Oncologist. 2017;23(3):360‐366.
542 |   SCHEER Et al.
 56. Emambux S, Kind M, Le Loarer F, et al. Clinical activity of eribu-
lin in advanced desmoplastic small round‐cell tumor. Anticancer 
Drugs. 2017;28(9):1053‐1055.
 57. De Sanctis R, Bertuzzi A, Bisogno G, et al. Imatinib mesylate in 
desmoplastic small round cell tumors. Future Oncol. 2017;13(14): 
1233‐1237.
 58. Italiano A, Kind M, Cioffi A, et al. Clinical activity of sunitinib 
in patients with advanced desmoplastic round cell tumor: a case 
series. Target Oncol. 2013;8(3):211‐213.
 59. de Araujo RA, Araujo BJ. Desmoplastic small round cell tumor: re-
port of 2 cases treated with chemotherapy alone or in combination 
with bevacizumab. Case Rep Oncol. 2014;7(1):102‐108.
 60. Betrian S, Bergeron C, Blay JY, et al. Antiangiogenic effects in 
patients with progressive desmoplastic small round cell tumor: data 
from the French national registry dedicated to the use of off‐la-
beled targeted therapy in sarcoma (OUTC's). Clin Sarcoma Res. 
2017;7:10.
 61. Forlenza CJ, Kushner BH, Kernan N, et al. Myeloablative chemo-
therapy with autologous stem cell transplant for desmoplastic small 
round cell tumor. Sarcoma. 2015;2015:269197.
 62. Schwarz RE, Gerald WL, Kushner BH, et al. Desmoplastic small 
round cell tumors: prognostic indicators and results of surgical 
management. Ann Surg Oncol. 1998;5(5):416‐422.
 63. Honore C, Atallah V, Mir O, et al. Abdominal desmoplastic small 
round cell tumor without extraperitoneal metastases: Is there a 
benefit for HIPEC after macroscopically complete cytoreductive 
surgery? PLoS ONE. 2017;12(2):e0171639.
 64. Hayes‐Jordan A. Cytoreductive surgery followed by hyperthermic 
intraperitoneal chemotherapy in DSRCT: progress and pitfalls. 
Curr Oncol Rep. 2015;17(8):38.
 65. Atallah V, Honore C, Orbach D, et al. Role of adjuvant radiation 
therapy after surgery for abdominal desmoplastic small round cell 
tumors. Int J Radiat Oncol Biol Phys. 2016;95(4):1244‐1253.
SUPPORTING INFORMATION
Additional supporting information may be found online in 
the Supporting Information section at the end of the article.    
How to cite this article: Scheer M, Vokuhl C, Blank B, 
et al. Desmoplastic small round cell tumors: 
Multimodality treatment and new risk factors. Cancer 
Med. 2019;8:527–542. https://doi.org/10.1002/
cam4.1940
